Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Alkermes ( (ALKS) ).
On September 8, 2025, Alkermes announced positive results from its Vibrance-1 phase 2 study of alixorexton, an investigational treatment for narcolepsy type 1, at the World Sleep Congress. The study demonstrated significant improvements in wakefulness, cognition, and fatigue, with alixorexton being well tolerated across all doses. These findings highlight the potential of alixorexton as a new treatment option for narcolepsy type 1, supporting Alkermes’ position in the field of neuroscience and orexin-targeted therapies.
The most recent analyst rating on (ALKS) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.
Alkermes receives a strong overall score driven by robust financial performance and positive earnings call highlights. The company’s solid cash position and successful clinical trials support future growth prospects. Technical indicators show positive momentum, though caution is warranted due to potential overbought conditions.
To see Spark’s full report on ALKS stock, click here.
More about Alkermes
Alkermes plc operates in the pharmaceutical industry, focusing on the development of innovative medicines for the treatment of central nervous system disorders. The company is involved in producing treatments for conditions such as narcolepsy, with a focus on orexin-targeted therapeutics.
Average Trading Volume: 1,823,090
Technical Sentiment Signal: Strong Buy
Current Market Cap: $4.94B
Learn more about ALKS stock on TipRanks’ Stock Analysis page.